Name | Insulin degludec |
---|---|
Synonyms |
(1A-21A),(1B-29B)-Insulin (human), 29B-[N6-[N-(15-carboxy-1-oxopentadecyl)-L-γ-glutamyl]-L-lysine]-
N6,29B-[N-(15-carboxypentadecanoyl)-L-γ-glutamyl]-des-30B-L-threonine-human insulin Insulin degludec |
Description | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes[1][2]. |
---|---|
Related Catalog | |
Target |
IC50: 19.59 nM/L (insulin receptor)[2] |
In Vitro | Insulin degludec (0.001-1000 nM; 12 h) binds with insulin receptor with an IC50 value of 19.59 nM/L[2]. Insulin degludec (200 nM; 10 min) increases glucose uptake in HL-1 cells[2]. Western Blot Analysis[2] Cell Line: HL-1 cardiomyocytes Concentration: 200 nM Incubation Time: 0-60 min Result: Decreased the level of Akt phosphorylation after 5 and 10 min treatment. |
In Vivo | Insulin degludec (5 U/kg; s.c. once daily for 30 days) affects glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia[1]. Animal Model: Male Swiss mice with diabetes[1] Dosage: 5 U/kg Administration: Subcutaneous injection; 5 U/kg once daily for 30 days Result: Showed a fast response to insulin-induced hypoglycemia with a glycemic level at or slightly under 100 mg/dl after 60 min and this response effect can be abolished by cortisol. Diminished rates of glucose production and showed a low lactate production in livers. Increased the number of hepatocytes. |
References |
Molecular Formula | C274H408N64O81S6 |
---|---|
Molecular Weight | 6103.97204 |